OUR SERVICES

MAD7 Gene Editing

While CRISPR/Cas9 transformed modern biology, its complex licensing model often requires agreements with multiple organizations.

Fortunately, MAD7 was introduced by Inscripta, Inc. in 2017 to provide the scientific community with broader access to advanced genome editing technology.

How MAD7 Compares to Cas9

MAD7 (ErCas12a) is an RNA-guided nuclease with distinct functional benefits over standard Cas9:

Single-RNA System: Requires only one RNA species to target DNA sequences.

Sticky-End Cleavage: Produces staggered double-strand breaks instead of blunt ends.
Expanded PAM Diversity: Targets T-rich PAM sequences (5′-TTTN-3′ / 5′-CTTN-3′) rather than G-rich sites (5′-NGG-3′).

MAD7-based gene editing is backed by years of validated success in hiPSC lines and HEK293 cells.

MAD7 Applications

MAD7 can be used for many of the same applications as CRISPR/Cas9, including:

Cell line engineering	Product development
Point mutations	Cell therapy
Knock-outs	Gene therapy (producer lines)
Knock-ins (less than 3 kb)	Antibody or protein expression

Ready to explore how MAD7 can elevate your research?